INCAGN01949

DRUG2 trials

Sponsors

Incyte Biosciences International Sàrl

Conditions

Advanced MalignanciesMetastatic Cancer

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

CompletedNCT02923349

Incyte Biosciences International SàrlAdvanced Malignancies, Metastatic Cancer

Start: 2016-10-31End: 2019-03-26Updated: 2025-08-24

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

CompletedNCT03241173

Incyte Biosciences International SàrlAdvanced Malignancies

Start: 2017-10-09End: 2019-09-17Updated: 2022-09-27

Related Papers

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-10-0187 citations

Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells

Cancer Research2017-07-016 citations